dementia scale revised points (Hasegawa Co Ltd)
86
Structured Review
Hasegawa Co Ltd
dementia scale revised points
Dementia Scale Revised Points, supplied by Hasegawa Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/point+scale/dementia+scale/pmc12907741-4-1-0
Average 86 stars, based on 1 article reviews
Dementia Scale Revised Points, supplied by Hasegawa Co Ltd, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/point+scale/dementia+scale/pmc12907741-4-1-0
Average 86 stars, based on 1 article reviews
dementia scale revised points - by Bioz Stars,
2026-11
86/100 stars
Images
Related Articles
other:Article Title: Consecutive Serious Medical Concomitants Associated With Extremely Severe Anorexia Nervosa in a Patient With Body Mass Index of 10.2 Kilograms per Square Meter: A Case Report Article Snippet: On hospital day 87, we assessed her cognitive function for the first time using the Article Title: Relationship between regional cerebral metabolism and consciousness disturbance in traumatic diffuse brain injury without large focal lesions: an FDG-PET study with statistical parametric mapping analysis Article Snippet: Group A had 22 patients (mean age 38.9 (SD 15.5) years, range 17–66 years; 13 men and 9 women) in a state with higher brain dysfunction; they were able to communicate through language, but had disturbed cognitive function (memory, attention and executive functions, slowed information processing, and modifications of behaviour and personality) on neuropsychological Article Title: Trading or coercion? Variation in male mating strategies between two communities of East African chimpanzees Article Snippet: Reproductive status was noted each day (if encountered) based on visual inspection of the sexual swelling, using a 3-point scale: I = no Single Photon Emission Computed Tomography:Article Title: Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technologic issues. Article Snippet: Imaging of positron-emitting radiotracers with standard nuclear medicine equipment dates back many decades.1-3 The clinical feasibility of imaging the highenergy photons of potassium-43 (373-keV and 619-keV photopeaks) and rubidium-81 (511-keV and 190-keV photopeaks) with a standard rectilinear scanner and gamma camera was first described in 1974.4,5 Cardiac application of positron emission tomography (PET) as a favorable technology for assessing regional myocardial blood flow, metabolism, and function began to emerge in 1980.6 The clinical utility of fluorine-18–labeled fluorodeoxyglucose (FDG) for differentiating viable from scarred myocardium with PET was shown in 1983.7 Preoperative identification of enhanced FDG uptake relative to perfusion (termed mismatch pattern) in an asynergic region by PET was shown to accurately predict functional improvement after revascularization.8 Despite such compelling data in the literature regarding the value of FDG PET for demonstrating myocardial viability, the cardiac applications of PET remain limited to only a few medical centers.. The most common reason ascribed for not adopting PET has been the high cost of both the initial investment and the maintenance of a PET-cyclotron facility.. The clinical feasibility of imaging FDG with highenergy collimator planar techniques kindled the interest of some investigators in 1989.9 In 1993 the feasibility of FDG imaging with single photon emission computed tomography (SPECT) was proposed.10 Because of the relatively long physical half-life of F-18 (110 minutes), off-site production and subsequent dissemination of F18–labeled tracers to nuclear cardiology laboratories became possible, thereby eliminating the need for an onsite cyclotron facility. Positron Emission Tomography:Article Title: Fluorine-18-deoxyglucose SPECT and coincidence imaging for myocardial viability: Clinical and technologic issues. Article Snippet: Imaging of positron-emitting radiotracers with standard nuclear medicine equipment dates back many decades.1-3 The clinical feasibility of imaging the highenergy photons of potassium-43 (373-keV and 619-keV photopeaks) and rubidium-81 (511-keV and 190-keV photopeaks) with a standard rectilinear scanner and gamma camera was first described in 1974.4,5 Cardiac application of positron emission tomography (PET) as a favorable technology for assessing regional myocardial blood flow, metabolism, and function began to emerge in 1980.6 The clinical utility of fluorine-18–labeled fluorodeoxyglucose (FDG) for differentiating viable from scarred myocardium with PET was shown in 1983.7 Preoperative identification of enhanced FDG uptake relative to perfusion (termed mismatch pattern) in an asynergic region by PET was shown to accurately predict functional improvement after revascularization.8 Despite such compelling data in the literature regarding the value of FDG PET for demonstrating myocardial viability, the cardiac applications of PET remain limited to only a few medical centers.. The most common reason ascribed for not adopting PET has been the high cost of both the initial investment and the maintenance of a PET-cyclotron facility.. The clinical feasibility of imaging FDG with highenergy collimator planar techniques kindled the interest of some investigators in 1989.9 In 1993 the feasibility of FDG imaging with single photon emission computed tomography (SPECT) was proposed.10 Because of the relatively long physical half-life of F-18 (110 minutes), off-site production and subsequent dissemination of F18–labeled tracers to nuclear cardiology laboratories became possible, thereby eliminating the need for an onsite cyclotron facility. |